Nanoparticles for dendritic cell-based immunotherapy

Purpose: Dendritic cell (DC)-based cancer immunotherapy is promising but limited by poor antigen immunogenicity, weak stability, and short in vivo half-life. Nanotechnology can protect antigens and adjuvants from premature degradation, enhance delivery to DCs, and improve therapeutic T cell responses. This review summarizes recent advances in nanoparticle-based systems for DC-targeted cancer immunotherapy.

Hypothesis: No formal experimental hypothesis. Central thesis: nanoparticle-based delivery systems can protect antigens and adjuvants, enhance their uptake by dendritic cells via passive or active targeting, promote DC maturation and migration, and elicit potent antigen-specific cytotoxic T lymphocyte responses for cancer immunotherapy.

Aims: Review recent advances in nanotechnology that improve the therapeutic efficacy of DC-based immunotherapies. - Summarize DC physiology and its role in antigen presentation and T cell response elicitation. - Describe inorganic, organic, and other nanoparticulate systems for DC-targeted antigen and adjuvant delivery. - Discuss passive and active targeting strategies for DCs. - Highlight imaging and tracking applications for monitoring DC migration. - Provide future perspectives on nanoparticle design for DC-based cancer immunotherapy.

Delivery system: Inorganic nanoparticles: gold nanoparticles (AuNPs) of 10, 22, 33, 60, and 80 nm for OVA peptide and CpG delivery; superparamagnetic iron oxide (SPIO) nanoparticles for MRI tracking; Fe₃O₄-ZnO core-shell nanoparticles for CEA antigen delivery; hybrid imaging nanoprobes (HINP) combining quantum dots and SPIO; ⁶⁷Ga-labeled iron oxide micelles; fluorescent magnetic nanoparticles (α-AP-fmNPs); upconversion nanoparticles (UCNPs) coated with PEG and PEI. - Organic nanoparticles: PLGA nanoparticles for OVA, TRP2, CpG-ODN, MPL, R837, poly(I:C), and tetanus toxoid; liposomes (stealth, cationic, magnetite cationic) for OVA, CpG, HMGB1-derived peptides, and hyperthermia; mannosylated PAMAM dendrimers; CpG-loaded cationic gelatin nanoparticles; Gd@C₈₂(OH)₂₂ fullerene derivatives; calcium phosphate (CaP) nanoparticles; graphene oxide nanosheets. - Payloads: tumor-associated antigens (OVA, TRP2, CEA, survivin peptide, hemagglutinin), adjuvants/TLR ligands (CpG-ODN, MPL, R837, poly(I:C), 7-acyl lipid A), model antigens (tetanus toxoid, RFP), and imaging agents (iron oxide, quantum dots, ICG, ⁶⁷Ga). - Targeting mechanisms: passive targeting (size-dependent lymph node drainage; <200 nm for lymph node-resident DCs, >500 nm for skin-resident DCs, optimal 40–50 nm); active targeting to DC surface receptors (TLRs, C-type lectin receptors including DEC-205/CD205, Clec9A, mannose receptor, DCIR2; CD11c; DC-SIGN). - Imaging modalities: MRI, NIR fluorescence, two-photon microscopy, SPECT, PET, bioluminescence, planar gamma scintigraphy.

Approach: Review of preclinical literature. In vitro systems include bone marrow-derived DCs (BMDCs), human DCs, and DC cell lines. In vivo models include mouse footpad injection models, B16 melanoma, B16-OVA melanoma, Lewis lung carcinoma (LLC), E.G7-OVA lymphoma, CEA-transgenic mice, and tumor challenge models. Clinical context includes prior DC vaccine trials for melanoma, prostate cancer, and glioma. Most discussed systems remain preclinical.

Key methods: Nanoparticle characterization: size, surface charge, morphology, loading efficiency. - DC uptake and internalization: flow cytometry, confocal microscopy, TEM. - DC maturation and activation: expression of CD40, CD80, CD83, CD86, MHC class I/II; cytokine secretion (IL-1, IL-6, IL-12p70, TNF-α, IFN-γ); CCR7 expression. - T cell responses: antigen-specific CD8⁺ and CD4⁺ T cell proliferation, IFN-γ production, CTL activity, tetramer staining. - In vivo imaging and tracking: MRI, NIR fluorescence, SPECT, two-photon microscopy. - Antitumor efficacy: tumor growth inhibition, tumor area/weight, survival, metastasis counts.

Key results: PLGA-conjugated or encapsulated Hp91 peptide activated DCs 5-fold (encapsulated) and 20-fold (surface-conjugated) more potently than free peptide. - Co-delivery of TRP2 and 7-acyl lipid A in PLGA NPs significantly increased IFN-γ secretion by TRP2-specific CD8⁺ T cells, elevated pro-inflammatory cytokines (IL-2, IL-6, IL-12, IFN-γ, TNF-α), decreased VEGF, and produced the smallest tumor area/weight among treatment groups in B16 melanoma-bearing mice. - Gold nanoparticle cocktail (AuNP60/OVAp + AuNP80/CpG-ODNs) increased OVA-specific CD8⁺ T cells in liver-draining lymph nodes and spleen by 6.5-fold and 3.4-fold, respectively, compared with CpG-ODNs/OVAp-pulsed DCs. - AuNP vaccine size influenced efficacy: larger vaccines in the 10–33 nm range were internalized better by DCs and elicited superior antigen-specific T-cell immunity; size threshold for multifunctional T-cell response was 10–22 nm. - PLGA NPs co-delivering OVA and poly(I:C) or CpG-ODNs enhanced MHC class I-restricted OVA presentation ~2-fold versus OVA alone; mixture of NPs enhanced presentation 2-fold and antigen-specific CD8⁺ T cell proliferation 3-fold. - CpG-coated PLGA NPs encapsulating tumor-associated antigen (CpG-NP-Tag) enhanced DC maturation (CD80, CD86, IL-12) and attenuated tumor growth and angiogenesis via IFN-γ and enhanced CTL function. - Magnetite cationic liposomes (MCLs) plus hyperthermia at 43°C upregulated MHC class I/II, CD80, CD86, and CCR7 on DCs; combination with DC therapy achieved complete tumor regression in 6/10 mice surviving over 100 days. - Liposomes engrafted with pHMGB-89 or pHMGB-106 peptides potently induced OVA-specific IFN-γ-producing CD8⁺ T lymphocytes and antibodies, and inhibited tumor growth and metastasis in B16-OVA melanoma-challenged mice. - CpG-loaded cationic gelatin nanoparticles with OVA increased OVA-specific CD8⁺ T cell number and induced protective antitumor response in B16-OVA challenged mice. - α-AP-fmNP-labeled DCs with magnetic pull force showed 11.4-fold higher fluorescence in popliteal lymph nodes, increased CD8⁺ T cell proliferation, IFN-γ production, augmented antigen-specific killing, and markedly delayed tumor growth.

Interpretation: Nanoparticles can deliver antigens and adjuvants to DCs, protect them from degradation, enhance DC activation and maturation, promote DC migration to lymphoid organs, and elicit potent antigen-specific T cell responses. The combination of nanoparticles with multiple imaging techniques enables tracking of DC trafficking to optimize DC-based immunotherapy. The authors conclude that nanoparticle-based delivery systems show great promise for improving DC-based cancer immunotherapy.

Limitations: Review article; no primary data. - Most systems remain preclinical; few clinical trials of nanoparticle-based DC vaccines. - DC vaccine manufacturing is limited by the process of drawing blood and preparing autologous vaccines from PBMCs. - Potential risk of autoimmune responses from self-antigens or tumor-lysate antigens shared with normal tissues. - Optimal dosing, timing, and scheduling of combination therapy need careful consideration. - The fate of nanoparticles after delivery to DCs and the mechanisms of antigen processing/presentation require further study. - Need for standardized methods to evaluate DC nanoimmunotherapy efficacy. - Scalability, quality control, and regulatory pathways for clinical translation remain challenges.